✦ LIBER ✦

O33 SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 mg AND 50 mg DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

✍ Scribed by Lagging, M.; Brown, A.; Weiland, O.R.; Mantry, P.; Ramji, A.; Weilert, F.; Vierling, J.M.; Talaty, J.; Gendrano, I.N.; Hwang, P.; Zhang, B.; Wahl, J.; Robertson, M.; Mobashery, N.

Book ID: 122305766
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 59 KB
Volume: 60
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(14)60035-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P777 DOSE-DEPENDENT PHARMACOKINETICS FOR

P777 DOSE-DEPENDENT PHARMACOKINETICS FOR MK-5172 25 mg, 50 mg, AND 100 mg ONCE-DAILY FOR 12 WEEKS IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

✍ Caro, L.; Talaty, J.; Morrison, M.; Zhang, S.; Guo, Z.; Gendrano III, I.N.; Hwan 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 61 KB

P1234 SAFETY AND EFFICACY OF MK-5172 PLU

P1234 SAFETY AND EFFICACY OF MK-5172 PLUS PEGINTERFERON ALFA-2b AND RIBAVIRIN (PR) IN CIRRHOTIC AND NON-CIRRHOTIC TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G)1 INFECTION

✍ Hezode, C.; Bruno, S.; Jacobson, I.; Serfaty, L.; Kwo, P.; Zhou, A.; Gilbert, C. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 60 KB